FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma
The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 11, 2023 Category: Transplant Surgery Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Aphexda (motixafortide) to Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
Aphexda is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade
One dosage of Aphexda plus filgrastim enabled a majority of patients to achieve the collection goal of≥ 6 million... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 11, 2023 Category: Drugs & Pharmacology Source Type: news
Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma
(MedPage Today) -- The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on Monday.
Recent advances in... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - September 11, 2023 Category: Surgery Source Type: news
NPPA fixes retail price of 74 drug formulations
The NPPA said it has also revised the ceiling price of 80 scheduled formulations (NLEM 2022) including the one to treat epilepsy and neutropenia. The ceiling price of one tablet (200mg) of Sodium Valproate has been fixed at Rs 3.20. Similarly, the ceiling price of Filgrastim injection (one vial) has been fixed at Rs 1,034.51. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2023 Category: Pharmaceuticals Source Type: news
Releuko (Filgrastim-ayow Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2022 Category: Drugs & Pharmacology Source Type: news
Oncology Care Model Reduces Cost of Supportive Care Meds Oncology Care Model Reduces Cost of Supportive Care Meds
The Oncology Care Model led to notable reductions in the use of the pricy monoclonal antibody denosumab, more rapid adoption of the biosimilar filgrastim, and more selective use of costly antiemetics.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
February 28, 2022 -- The United States (U.S.) Food and Drug Administration (FDA) has approved Releuko (filgrastim-ayow), a biosimilar to Neupogen (filgrastim).
The FDA approval was based on a review of data that demonstrated a high degree of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2022 Category: Drugs & Pharmacology Source Type: news
Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines.
Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S.
The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2021 Category: Biotechnology Authors: Laura Newpoff Source Type: news
Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines.
Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S.
The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 29, 2021 Category: American Health Authors: Laura Newpoff Source Type: news
Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news
Nivestym (Filgrastim-aafi Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 20, 2021 Category: Drugs & Pharmacology Source Type: news
filgrastim (Neupogen)
Title: filgrastim (Neupogen)Category: MedicationsCreated: 9/19/2000 12:00:00 AMLast Editorial Review: 8/2/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 2, 2019 Category: Cancer & Oncology Source Type: news
Savings With Biosimilar Filgrastim Unclear Savings With Biosimilar Filgrastim Unclear
Projected cost savings from switching to biosimilar filgrastim from the reference drug depend on the data analyzed.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
Amgen Donates $93 Million Worth of Cancer Medicines
THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab).
Patients will access the donated medicines through Direct Relief-partner hospitals and clinics in the following countries: Armenia, Ca...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Early Insights into Biosimilar Cost Savings in the United States
A recent study inJAMA Oncologyexamined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
